In contrast, while the modulation of HMGB1 has been postulated to have anti-ictogenic activity in experimental epilepsy models, as described earlier, inhibition via glycyrrhizin in the same TBI model did not alter seizure outcomes [239]. The gene discussed is HMGB1; the disease is epilepsy.